DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for pemphigus vulgaris — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePemphigus vulgaris maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pemphigus vulgaris is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
inosine monophosphate dehydrogenase 1 (IMPDH1) — IMPDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cprdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1JCN · 2.5 Å · ligand 6-CHLOROPURINE RIBOSIDE, 5'-MONOPHOSPHATE (CPR). Experimental structure, not a prediction.
What the evidence adds up to
In an endemic region of Brazil, eight patients with a mucocutaneous disease clinically and histologically consistent with pemphigus vulgaris were found to have antidesmoglein 3 autoantibodies by cold immunoprecipitation (all eight) and by ELISA (six of eight). Four of the eight also had antidesmoglein 1 autoantibodies by both methods. Among 27 healthy relatives living in the same endemic area, four had antidesmoglein 3 autoantibodies and six had antidesmoglein 1 autoantibodies by cold immunoprecipitation. These serological findings were interpreted as evidence of a new endemic variant of pemphigus vulgaris.
In 1956, nine patients with pemphigus vulgaris were treated with corticotropin (ACTH). All but one were described as moribund at some point and would almost certainly have died without the drug. Corticotropin never failed to suppress blister formation in these patients. All nine experienced remissions during which no corticotropin was needed, and all had exacerbations requiring greatly increased doses. Side-effects were reported as minimal, and the maintenance dose was constant enough to allow outpatient therapy for indefinite periods.
A 2013 case report describes a severe, life-threatening course of pemphigus vulgaris complicated by sepsis from azathioprine-induced bone marrow suppression. The patient was successfully managed with combination therapy including corticosteroid pulse therapy, which the authors argue still plays an important role despite the current neglect of pulse corticosteroids in first-line treatment. The report notes that severe forms resistant to standard treatment carry a mortality of 5–10%, and that current popular procedures include intravenous immunoglobulins and rituximab.
A 1987 review of three Asian males with pemphigus vulgaris, aged 30–40 years, found clinical features and disease course similar to those seen in European patients. The authors suggest, based on a literature review, an increased incidence in young Asians and remission induced by lower doses of immunosuppressives. What is still missing is prospective data comparing outcomes in different ethnic groups, controlled trials of pulse corticosteroids versus newer biologics, and any evidence that the endemic Brazilian variant responds differently to standard treatments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 2007 · 46 citations
Endemic Pemphigus Vulgaris
AbstractBACKGROUND: Investigators from Brasilia, Brazil, observed several patients with a mucocutaneous disease that resembles pemphigus vulgaris clinically and histologically but with epidemiological features of fogo selvagem. Our objective was to characterize antidesmoglein 3 and antidesmoglein 1 autoantibody profiles in these unique patients who reside in Goiânia and Brasilia, Brazil, known endemic regions of fogo selvagem. OBSERVATIONS: We performed serological evaluation of 8 patients with a mucocutaneous disease clinically and histologically consistent with pemphigus vulgaris, as well as 27 healthy relatives of patients with fogo selvagem who reside in these endemic areas. Serum samples from all 8 patients bound desmoglein 3 by cold immunoprecipitation and from 6 patients by enzyme-linked immunosorbent assay, while serum samples from 4 patients bound desmoglein 1 by cold immunoprecipitation and by enzyme-linked immunosorbent assay. Antidesmoglein 3 autoantibodies were detected in 4 of 27 healthy donors by cold immunoprecipitation and by enzyme-linked immunosorbent assay, whereas antidesmoglein 1 autoantibodies were detected in 6 individuals by cold immunoprecipitation and in 3 individuals by enzyme-linked immunosorbent assay. CONCLUSION: These findings provide serological evidence of a new endemic variant of pemphigus vulgaris.
LONG-TERM MANAGEMENT OF PEMPHIGUS VULGARIS WITH CORTICOTROPIN (ACTH)
Abstract• Nine patients with pemphigus vulgaris were followed through periods of remission and exacerbation. All but one were at one time moribund and would almost certainly have died if corticotropin had not been available to them. All experienced remissions during which no corticotropin was needed, and all at one time or another had exacerbations that required greatly increased doses of corticotropin for control. Corticotropin never failed to suppress the blister formation. Side-effects were minimal. Except during the remissions, which are infrequent, the dosage needed has been remarkably constant, so that the therapy can be continued on an outpatient basis for indefinite periods of time.
Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy
AbstractSevere forms of pemphigus vulgaris (PV) that are resistant to standard treatment present a life-threatening disease with a mortality of 5-10%. The treatment is usually individualized. The most popular procedures used today include intravenous applications of immunoglobulins and rituximab. Currently the common use of pulse corticosteroids, often in first-line treatment, is being neglected. This particular case documented the severity of the disease and also the need for combined and comprehensive care, in which corticosteroid pulse therapy still plays an important role.
Clinical and Experimental Dermatology · 1987 · 2 citations
Pemphigus vulgaris in young Asians-a report of three cases and review of the literature
AbstractPemphigus vulgaris in three Asian males is described. The disease occurred in the 30–40-year age group, but otherwise the clinical features and course of the disease were similar to that seen in the European. Review of the literature suggests an increased incidence in young Asians with remission induced by lower doses of immunosuppressives.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
